An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
Status:
Recruiting
Trial end date:
2022-10-21
Target enrollment:
Participant gender:
Summary
This is a clinical study in adult participants with moderate to severe atopic dermatitis
(AD).
The purpose of the study is to test a new medicine (LEO 138559) given by injection to see if
it works to treat AD and what the side effects are when compared with a placebo injection
with no medical ingredient.
The study will last up to 36 weeks for each participant. The study will include a treatment
period of 16 weeks, during which the participants will receive the injections, followed by a
period of 16 weeks without treatment with the main purpose of continuing safety evaluations.
The participants will regularly visit the clinic for tests and the study doctor will evaluate
their AD. The participants will also be asked to answer questions about their AD symptoms and
quality of life.